Systematic Reviews
Copyright ©The Author(s) 2021.
World J Nephrol. Jul 25, 2021; 10(4): 59-75
Published online Jul 25, 2021. doi: 10.5527/wjn.v10.i4.59
Table 1 Study characteristics
Ref.
Country
Study type
n
Subject
Age, yr
Male, %
AUC for mortality (95%CI)
Follow-up
Dara et al[19], 2004United StatesRetrospective476HD patients6658APACHE III on hospital mortality 0.76 (0.66-0.84) and 30-d mortality 0.78 (0.68-0.86); SOFA score on hospital mortality 0.65 (0.55-0.75) and 30-d mortality 0.66 (0.55-0.76)-
Miskulin et al[20], 2004United StatesProspective1779Outpatient dialysis patients6253ICED 0.72 (0.69-0.75); CCI 0.67 (0.65-0.70); Wright- Khan indices 0.68 (0.65-0.70); Davies indices 0.68 (0.65-0.70)1 yr
Wang et al[21], 2007Hong KongProspective238ESRD on continuous PD55.751.3cTnT 0.774 (0.706-0.841); High sensitivity CRP 0.691 (0.614-0.7683 yr
Sun et al[22], 2008ChinaProspective217HD patients65.462.2BNP on CV events 0.61 (0.57-0.70); NT-proBNP on CV events 0.83 (0.75-0.91)2 yr
Selim et al[23], 2010MacedoniaProspective125HD patients48.8-BNP > 1200 pg/mL on CV mortality 0.612 (0.473-0.750); NT-proBNP > 10000 pg/mL on CV mortality 0.747 (0.677-0.816)2 yr
Breidthardt et al[24], 2011SwitzerlandRetrospective113HD patients67.960BNP: all-cause mortality 0.70 (0.60-0.81); BNP: CV mortality 0.82 (0.73-0.90)735 d
Tomaszuk-Kazberuk et al[25], 2011PolandProspective39HD patients5963.8Perfusion defects on MCE for death 0.752 (0.582-0.878)3 yr
Chiang et al[26], 2016TaiwanProspective132ESRD patients on PD53.747.0Short-term detrended fluctuation analysis (DFAα1) < 0.95-0.761 (0.617-0.905)34 mo
Sato et al[27], 2017JapanRetrospective302HD patients63.465.4Neutrophil-lymphocyte ratio for 1-yr mortality 0.791 (0.602-0.980)1 yr
Wang et al[28], 2018ChinaProspective300CKD 3-56053.6UPCR for mortality 0.78 (0.72-0.84); eGFR for mortality 0.75 (0.69-0.81); Mitral E/E’ ratio for mortality 0.74 (0.67-0.80); LV mass index for mortality 0.72 (0.65-0.79); LVEF for mortality 0.50 (0.42-0.58)68 mo
Wlazeł et al[29], 2018PolandProspective64HD patients6666 SuPAR 0.84 (0.7-0.94)3 yr
Danial et al[30], 2019MalaysiaRetrospective160CKD 3-5 with adverse drug reaction-57.5Mortality risk score model 0.789 (0.700-0.878)Few weeks (until end date of ADRs)
Jagadeswaran et al[31], 2019IndiaProspective129Pre-dialysis CKD 3-550.651.2Malnutrition inflammation score for mortality 0.709 (0.604-0.815)36 mo
Mukai et al[32], 2019SwedenProspective261CKD 5 (both dialysis and non-dialysis)5666Skin autofluorescence for all-cause mortality 0.78 (0.71-0.86); Augmentation index for all-cause mortality 0.81 (0.75-0.87)25 mo
Pladys et al[33], 2020FranceRetrospective9052ESRD on dialysis68.4-Rennes score model 1(REIN and SNDS data) 0.789 (0.761–0.816); Model 2 (REIN data only) 0.794 (0.768-0.821); Wright classification 0.631 (0.621-0.639); Modified CCI 0.703 (0.689-0.716)1 yr
Shahidi et al[34], 2020IranRetrospective824HD patients57.961.8Hemoglobin change on mortality 0.61 (0.56-0.65)24.08 mo
Gan et al[35], 2021AustraliaProspective243CKD 3-465.662.6Left atrial reservoir strain for CV death 0.84 (0.76-0.90)3.9 yr
Rroji et al[36], 2021AlbaniaProspective125ESRD on dialysis52.460.0CRP on CV mortality 0.80 (0.73-0.92); Left ventricular mass index on CV mortality 0.76 (0.65-0.88); Ratio of early mitral inflow velocity/annular diastolic velocity (E/E’) on CV mortality 0.75 (0.64-0.86); Systolic pulmonary artery pressure on CV mortality 0.80 (0.68-0.92); Pulse pressure on CV mortality 0.72 (0.60-0.84)2 yr